{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:49:25Z","timestamp":1793339365965,"version":"4.5.0"},"reference-count":175,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.drudis.2021.07.027","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T12:07:14Z","timestamp":1627992434000},"page":"2816-2838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road"],"prefix":"10.1016","volume":"26","author":[{"given":"Bashkim","family":"Kadriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Musazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenessa N.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E.","family":"Kalynchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector J.","family":"Caruncho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4670-8664","authenticated-orcid":false,"given":"Maurizio","family":"Popoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.07.027_b0005","doi-asserted-by":"crossref","unstructured":"Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006; 71: 1273\u201388.","DOI":"10.1016\/j.bcp.2005.12.022"},{"key":"10.1016\/j.drudis.2021.07.027_b0010","series-title":"Glutamate-based therapies for psychiatric disorders \u2013 Milestones in drug therapy","first-page":"39","article-title":"Positive allosteric modulation of AMPA receptors: a novel potential antidepressant therapy","author":"Nisenbaum","year":"2010"},{"key":"10.1016\/j.drudis.2021.07.027_b0015","doi-asserted-by":"crossref","unstructured":"Skolnick P. Glutamate-based therapies for psychiatric disorders \u2013 Milestones in drug therapy, Basel: Birk\u00e4user; 2010.","DOI":"10.1007\/978-3-0346-0241-9"},{"key":"10.1016\/j.drudis.2021.07.027_b0020","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol Med"},{"key":"10.1016\/j.drudis.2021.07.027_b0025","doi-asserted-by":"crossref","unstructured":"Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 2015; 5: e632.","DOI":"10.1038\/tp.2015.136"},{"key":"10.1016\/j.drudis.2021.07.027_b0030","doi-asserted-by":"crossref","unstructured":"Zhang JC, Li SX, Hashimoto K. R (\u2013)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 2014; 116: 137\u201341.","DOI":"10.1016\/j.pbb.2013.11.033"},{"key":"10.1016\/j.drudis.2021.07.027_b0035","unstructured":"U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Published March 5, 2019. Accessed July 27, 2021."},{"key":"10.1016\/j.drudis.2021.07.027_b0040","doi-asserted-by":"crossref","unstructured":"Kadriu B, Musazzi L, Henter ID, Graves M, Popoli M, Zarate CA, Jr. Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments. Int J Neuropsychopharmacol 2019; 22: 119\u201335.","DOI":"10.1093\/ijnp\/pyy094"},{"key":"10.1016\/j.drudis.2021.07.027_b0045","doi-asserted-by":"crossref","unstructured":"Park LT, Kadriu B, Gould TD, Zanos P, Greenstein D, Evans JW, et al. A randomized trial of the N-methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression. Int J Neuropsychopharmacol 2020; 23: 417\u201325.","DOI":"10.1093\/ijnp\/pyaa025"},{"key":"10.1016\/j.drudis.2021.07.027_b0050","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/01.pra.0000462606.17725.93","article-title":"Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent","volume":"21","author":"Preskorn","year":"2015","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.drudis.2021.07.027_b0055","doi-asserted-by":"crossref","first-page":"19ac13138","DOI":"10.4088\/JCP.19ac13138","article-title":"Not so fast: recent successes and failures in treating depression","volume":"81","author":"Kadriu","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.drudis.2021.07.027_b0060","doi-asserted-by":"crossref","unstructured":"Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Res 2018; 7: F1000 Faculty Rev-659.","DOI":"10.12688\/f1000research.14344.1"},{"key":"10.1016\/j.drudis.2021.07.027_b0065","doi-asserted-by":"crossref","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 2018; 70: 621\u201360.","DOI":"10.1124\/pr.117.015198"},{"key":"10.1016\/j.drudis.2021.07.027_b0070","doi-asserted-by":"crossref","unstructured":"Gould TD, Zanos P, Zarate CA, Jr. Ketamine mechanism of action: separating the wheat from the chaff. Neuropsychopharmacology 2017; 42: 368\u20139.","DOI":"10.1038\/npp.2016.210"},{"key":"10.1016\/j.drudis.2021.07.027_b0075","doi-asserted-by":"crossref","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016; 533: 481\u20136.","DOI":"10.1038\/nature17998"},{"key":"10.1016\/j.drudis.2021.07.027_b0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fnana.2013.00023","article-title":"Brain damages in ketamine addicts as revealed by magnetic resonance imaging","volume":"7","author":"Wang","year":"2013","journal-title":"Front Neuroanat"},{"key":"10.1016\/j.drudis.2021.07.027_b0085","doi-asserted-by":"crossref","unstructured":"Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22: 238\u201349.","DOI":"10.1038\/nm.4050"},{"key":"10.1016\/j.drudis.2021.07.027_b0090","doi-asserted-by":"crossref","unstructured":"Ionescu DF, Felicione JM, Gosai A, Cusin C, Shin P, Shapero BG, Deckersbach T. Ketamine-associated brain changes: a review of the neuroimaging literature. Harv Rev Psychiatry 2018; 26: 320\u201339.","DOI":"10.1097\/HRP.0000000000000179"},{"key":"10.1016\/j.drudis.2021.07.027_b0095","doi-asserted-by":"crossref","unstructured":"Rantamaki T, Kohtala S. Encoding, consolidation, and renormalization in depression: synaptic homeostasis, plasticity, and sleep integrate rapid antidepressant effects. Pharmacol Rev 2020; 72: 439\u201365.","DOI":"10.1124\/pr.119.018697"},{"key":"10.1016\/j.drudis.2021.07.027_b0100","doi-asserted-by":"crossref","first-page":"eaat8078","DOI":"10.1126\/science.aat8078","article-title":"Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation","volume":"364","author":"Moda-Sava","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.07.027_b0105","doi-asserted-by":"crossref","unstructured":"Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011; 69: 754\u201361.","DOI":"10.1016\/j.biopsych.2010.12.015"},{"key":"10.1016\/j.drudis.2021.07.027_b0110","doi-asserted-by":"crossref","unstructured":"Sarkar A, Kabbaj M. Sex differences in effects of ketamine on behavior, spine density, and synaptic proteins in socially isolated rats. Biol Psychiatry 2016; 80: 448\u201356.","DOI":"10.1016\/j.biopsych.2015.12.025"},{"key":"10.1016\/j.drudis.2021.07.027_b0115","doi-asserted-by":"crossref","unstructured":"Thelen C, Flaherty E, Saurine J, Sens J, Mohamed S, Pitychoutis P. Sex differences in the temporal neuromolecular and synaptogenic effects of the rapid-acting antidepressant drug ketamine in the mouse brain. Neuroscience 2019; 398: 182\u201392.","DOI":"10.1016\/j.neuroscience.2018.11.053"},{"issue":"7","key":"10.1016\/j.drudis.2021.07.027_b0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eurpsy.2013.10.005","article-title":"Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex","volume":"29","author":"Zhou","year":"2014","journal-title":"Eur Psychiatry"},{"issue":"5994","key":"10.1016\/j.drudis.2021.07.027_b0125","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.07.027_b0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.drudis.2021.07.027_b0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuropharm.2019.04.019","article-title":"Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine","volume":"153","author":"Shaffer","year":"2019","journal-title":"Neuropharmacology"},{"issue":"7659","key":"10.1016\/j.drudis.2021.07.027_b0140","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature22084","article-title":"Effects of a ketamine metabolite on synaptic NMDAR function","volume":"546","author":"Suzuki","year":"2017","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.drudis.2021.07.027_b0145","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2021.07.027_b0150","doi-asserted-by":"crossref","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. Zanos et al. reply. Nature 2017; 546: E4\u20135.","DOI":"10.1038\/nature22085"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.027_b0155","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1523\/JNEUROSCI.23-03-00847.2003","article-title":"How AMPA receptor desensitization depends on receptor occupancy","volume":"23","author":"Robert","year":"2003","journal-title":"J Neurosci"},{"issue":"19","key":"10.1016\/j.drudis.2021.07.027_b0160","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1113\/JP271844","article-title":"The dynamic AMPA receptor extracellular region: a platform for synaptic protein interactions","volume":"594","author":"Garc\u00eda-Nafr\u00eda","year":"2016","journal-title":"J Physiol"},{"key":"10.1016\/j.drudis.2021.07.027_b0165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.coph.2014.11.002","article-title":"AMPA receptor potentiators: from drug design to cognitive enhancement","volume":"20","author":"Partin","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"4976","key":"10.1016\/j.drudis.2021.07.027_b0170","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1126\/science.1699275","article-title":"Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS","volume":"249","author":"Sommer","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.07.027_b0175","doi-asserted-by":"crossref","unstructured":"Lykens NM, Coughlin DJ, Reddi JM, Lutz GJ, Tallent MK. AMPA GluA1-flip targeted oligonucleotide therapy reduces neonatal seizures and hyperexcitability. PLoS One 2017; 12: e0171538.","DOI":"10.1371\/journal.pone.0171538"},{"issue":"12","key":"10.1016\/j.drudis.2021.07.027_b0180","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1523\/JNEUROSCI.5613-09.2010","article-title":"Gating modes in AMPA receptors","volume":"30","author":"Prieto","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2021.07.027_b0185","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/emboj.2011.17","article-title":"Dynamics and allosteric potential of the AMPA receptor N-terminal domain","volume":"30","author":"Sukumaran","year":"2011","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2021.07.027_b0190","doi-asserted-by":"crossref","unstructured":"Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int J Neuropsychopharmacol 2013; 16: 69\u201382.","DOI":"10.1017\/S1461145712000016"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.027_b0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.tins.2007.01.006","article-title":"Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death","volume":"30","author":"Liu","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.drudis.2021.07.027_b0200","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.sbi.2019.05.004","article-title":"Structural biology of glutamate receptor ion channels: towards an understanding of mechanism","volume":"57","author":"Greger","year":"2019","journal-title":"Curr Opin Struct Biol"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.027_b0205","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.neuron.2017.04.009","article-title":"Structural and functional architecture of AMPA-type glutamate receptors and their auxiliary proteins","volume":"94","author":"Greger","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2021.07.027_b0210","doi-asserted-by":"crossref","unstructured":"Gandal MJ, Sisti J, Klook K, Leitman V, Liang Y, Thieu T, et al. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl Psychiatry 2012; 2: e142.","DOI":"10.1038\/tp.2012.69"},{"key":"10.1016\/j.drudis.2021.07.027_b0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/neuro.02.006.2008","article-title":"Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia","volume":"1","author":"Kehrer","year":"2008","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.drudis.2021.07.027_b0220","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jad.2018.05.078","article-title":"Abnormal early dynamic individual patterns of functional networks in low gamma band for depression recognition","volume":"238","author":"Bi","year":"2018","journal-title":"J Affect Disord"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.027_b0225","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/schbul\/sbv051","article-title":"Ketamine dysregulates the amplitude and connectivity of high-frequency oscillations in cortical-subcortical networks in humans: evidence from resting-state magnetoencephalography-recordings","volume":"41","author":"Rivolta","year":"2015","journal-title":"Schizophr Bull"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.027_b0230","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.euroneuro.2015.04.012","article-title":"Ketamine amplifies induced gamma frequency oscillations in the human cerebral cortex","volume":"25","author":"Shaw","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.027_b0235","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.biopsych.2016.02.009","article-title":"Bidirectional homeostatic regulation of a depression-related brain state by gamma-aminobutyric acidergic deficits and ketamine treatment","volume":"80","author":"Ren","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.027_b0240","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/mp.2011.31","article-title":"A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior","volume":"17","author":"Carl\u00e9n","year":"2012","journal-title":"Mol Psychiatry"},{"issue":"43","key":"10.1016\/j.drudis.2021.07.027_b0245","doi-asserted-by":"crossref","first-page":"11496","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J Neurosci"},{"issue":"13","key":"10.1016\/j.drudis.2021.07.027_b0250","doi-asserted-by":"crossref","first-page":"E3007","DOI":"10.1073\/pnas.1718883115","article-title":"Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy","volume":"115","author":"Widman","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.drudis.2021.07.027_b0255","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.drudis.2021.07.027_b0260","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuropharm.2015.07.028","article-title":"Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: direct inhibition and disinhibition","volume":"100","author":"Miller","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.027_b0265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrn2044","article-title":"Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks","volume":"8","author":"Bartos","year":"2007","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.027_b0270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12264-014-1484-6","article-title":"Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression","volume":"31","author":"Wang","year":"2015","journal-title":"Neurosci Bull"},{"issue":"7","key":"10.1016\/j.drudis.2021.07.027_b0275","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41380-018-0028-2","article-title":"Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects","volume":"24","author":"Nugent","year":"2019","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.027_b0280","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.neuroscience.2003.10.033","article-title":"Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus","volume":"123","author":"Arai","year":"2004","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.drudis.2021.07.027_b0285","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.mp.4001551","article-title":"Glutamate as a therapeutic target in psychiatric disorders","volume":"9","author":"Javitt","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.drudis.2021.07.027_b0290","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1476-5381.2010.00726.x","article-title":"Challenges for and current status of research into positive modulators of AMPA receptors","volume":"160","author":"Ward","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0295","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1523\/JNEUROSCI.2567-05.2005","article-title":"Mechanism of positive allosteric modulators acting on AMPA receptors","volume":"25","author":"Jin","year":"2005","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.027_b0300","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/11319230-000000000-00000","article-title":"Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders","volume":"70","author":"Malykh","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2021.07.027_b0305","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1471-4159.1992.tb11329.x","article-title":"Nootropic drugs positively modulate \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures","volume":"58","author":"Copani","year":"1992","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.027_b0310","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000057700","article-title":"Clinical efficacy of piracetam in cognitive impairment: a meta-analysis","volume":"13","author":"Waegemans","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"2","key":"10.1016\/j.drudis.2021.07.027_b0315","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1073\/pnas.91.2.777","article-title":"Facilitation of glutamate receptors enhances memory","volume":"91","author":"Staubli","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2021.07.027_b0320","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/138945007780618490","article-title":"Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior","volume":"8","author":"Arai","year":"2007","journal-title":"Curr Drug Targets"},{"issue":"S11","key":"10.1016\/j.drudis.2021.07.027_b0325","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nn935","article-title":"Memory enhancement: the search for mechanism-based drugs","volume":"5","author":"Lynch","year":"2002","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.027_b0330","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.npp.1301444","article-title":"A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia","volume":"33","author":"Goff","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"2-3","key":"10.1016\/j.drudis.2021.07.027_b0335","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0920-9964(01)00311-5","article-title":"Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series","volume":"57","author":"Marenco","year":"2002","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.027_b0340","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/cap.2006.16.525","article-title":"Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial","volume":"16","author":"Berry-Kravis","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0345","doi-asserted-by":"crossref","unstructured":"Murru L, Vezzoli E, Longatti A, Ponzoni L, Falqui A, Folci A, et al. Pharmacological modulation of AMPAR rescues intellectual disability-like phenotype in Tm4sf2-\/y mice. Cereb Cortex 2017; 27: 5369\u201384.","DOI":"10.1093\/cercor\/bhx221"},{"key":"10.1016\/j.drudis.2021.07.027_b0350","doi-asserted-by":"crossref","unstructured":"Tatsukawa T, Raveau M, Ogiwara I, Hattori S, Miyamoto H, Mazaki E, et al. Scn2a haploinsufficient mice display a spectrum of phenotypes affecting anxiety, sociability, memory flexibility and ampakine CX516 rescues their hyperactivity. Mol Autism 2019; 10: 15.","DOI":"10.1186\/s13229-019-0265-5"},{"issue":"7","key":"10.1016\/j.drudis.2021.07.027_b0355","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1523\/JNEUROSCI.18-07-02740.1998","article-title":"Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance","volume":"18","author":"Hampson","year":"1998","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.027_b0360","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-2999(02)01338-9","article-title":"Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model","volume":"440","author":"Knapp","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0365","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.biopha.2018.06.008","article-title":"Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain","volume":"105","author":"Radin","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.027_b0370","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbr.2009.09.048","article-title":"Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats","volume":"207","author":"Damgaard","year":"2010","journal-title":"Behav Brain Res"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.027_b0375","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/sj.npp.1301191","article-title":"The ampakine CX546 restores the prepulse inhibition and latent inhibition deficits in mGluR5-deficient mice","volume":"32","author":"Lipina","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.drudis.2021.07.027_b0380","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/aur.2066","article-title":"Hypothesis-driven investigations of diverse pharmacological targets in two mouse models of autism","volume":"12","author":"Rhine","year":"2019","journal-title":"Autism Res"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.027_b0385","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41593-019-0445-9","article-title":"Anterior cingulate cortex dysfunction underlies social deficits in Shank3 mutant mice","volume":"22","author":"Guo","year":"2019","journal-title":"Nat Neurosci"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.027_b0390","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1111\/ejn.12638","article-title":"Prolonged ampakine exposure prunes dendritic spines and increases presynaptic release probability for enhanced long-term potentiation in the hippocampus","volume":"40","author":"Chang","year":"2014","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.drudis.2021.07.027_b0395","doi-asserted-by":"crossref","unstructured":"Schitine C, Xapelli S, Agasse F, Sard\u00e0-Arroyo L, Silva AP, De Melo Reis RA, et al. Ampakine CX546 increases proliferation and neuronal differentiation in subventricular zone stem\/progenitor cell cultures. Eur J Neurosci 2012; 35: 1672\u201383.","DOI":"10.1111\/j.1460-9568.2012.08072.x"},{"issue":"27","key":"10.1016\/j.drudis.2021.07.027_b0400","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1523\/JNEUROSCI.6078-08.2009","article-title":"Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation","volume":"29","author":"Jourdi","year":"2009","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.027_b0405","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","article-title":"Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling","volume":"23","author":"Cavalleri","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1016\/j.drudis.2021.07.027_b0410","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1734-1140(13)71080-6","article-title":"Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test","volume":"65","author":"Wolak","year":"2013","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.027_b0415","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.neuropharm.2009.01.015","article-title":"BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slices","volume":"56","author":"Jourdi","year":"2009","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.027_b0420","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.neuroscience.2008.12.018","article-title":"Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression","volume":"159","author":"Lauterborn","year":"2009","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.drudis.2021.07.027_b0425","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00726-009-0412-y","article-title":"The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test","volume":"39","author":"Szewczyk","year":"2010","journal-title":"Amino Acids"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.027_b0430","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hipo.23168","article-title":"Hippocampal gamma rhythms during Y-maze navigation in the juvenile rat","volume":"30","author":"McHail","year":"2020","journal-title":"Hippocampus"},{"key":"10.1016\/j.drudis.2021.07.027_b0435","doi-asserted-by":"crossref","first-page":"RRN1182","DOI":"10.1371\/currents.RRN1182","article-title":"Rescuing the corticostriatal synaptic disconnection in the R6\/2 mouse model of Huntington\u2019s disease: exercise, adenosine receptors and ampakines","volume":"2","author":"Cepeda","year":"2010","journal-title":"PLoS Curr"},{"issue":"1-3","key":"10.1016\/j.drudis.2021.07.027_b0440","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00213-008-1325-2","article-title":"Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat","volume":"202","author":"Woolley","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.drudis.2021.07.027_b0445","first-page":"724","article-title":"CX691, as an AMPA receptor positive modulator, improves the learning and memory in a rat model of Alzheimer's disease","volume":"21","author":"Mozafari","year":"2018","journal-title":"Iran J Basic Med Sci"},{"issue":"6","key":"10.1016\/j.drudis.2021.07.027_b0450","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.npp.1301257","article-title":"Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers","volume":"32","author":"Wezenberg","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.027_b0455","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1007\/s12035-020-01954-x","article-title":"Antidepressant-like effects of CX717, a positive allosteric modulator of AMPA receptors","volume":"57","author":"Gordillo-Salas","year":"2020","journal-title":"Mol Neurobiol"},{"issue":"1-3","key":"10.1016\/j.drudis.2021.07.027_b0460","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00213-008-1360-z","article-title":"Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717","volume":"202","author":"Hampson","year":"2009","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.drudis.2021.07.027_b0465","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.pharep.2015.02.008","article-title":"Partial effects of the AMPAkine CX717 in a strain specific battery of tests for manic-like behavior in black Swiss mice","volume":"67","author":"Kara","year":"2015","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.drudis.2021.07.027_b0470","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2174\/156720511798192709","article-title":"Effects of the putative cognitive-enhancing ampakine, CX717, on attention and object recognition memory","volume":"8","author":"Zheng","year":"2011","journal-title":"Curr Alzheimer Res"},{"issue":"8","key":"10.1016\/j.drudis.2021.07.027_b0475","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/0269881111405353","article-title":"Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep","volume":"26","author":"Boyle","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0480","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-009-1598-0","article-title":"Chronic treatment with AMPA receptor potentiator Org 26576 increases neuronal cell proliferation and survival in adult rodent hippocampus","volume":"206","author":"Su","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.drudis.2021.07.027_b0485","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.phrs.2011.10.004","article-title":"The AMPA receptor potentiator Org 26576 modulates stress-induced transcription of BDNF isoforms in rat hippocampus","volume":"65","author":"Fumagalli","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2021.07.027_b0490","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1177\/0269881112458728","article-title":"Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial","volume":"26","author":"Nations KR","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0495","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.biopsych.2012.05.012","article-title":"A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit\/hyperactivity disorder","volume":"72","author":"Adler","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.drudis.2021.07.027_b0500","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00213-011-2554-3","article-title":"Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission","volume":"221","author":"Jardemark","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.drudis.2021.07.027_b0505","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.neuropharm.2017.06.009","article-title":"The AMPA receptor positive allosteric modulator S 47445 rescues in vivo CA3-CA1 long-term potentiation and structural synaptic changes in old mice","volume":"123","author":"Giralt","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0510","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.phrs.2017.04.019","article-title":"Upregulation of neurotrophins by S 47445, a novel positive allosteric modulator of AMPA receptors in aged rats","volume":"121","author":"Calabrese","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2021.07.027_b0515","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3389\/fphar.2017.00462","article-title":"S 47445 produces antidepressant- and anxiolytic-like effects through neurogenesis dependent and independent mechanisms","volume":"8","author":"Mendez-David","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0520","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pnpbp.2019.04.005","article-title":"S 47445 counteracts the behavioral manifestations and hippocampal neuroplasticity changes in bulbectomized mice","volume":"93","author":"Pilar-Cuellar","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.drudis.2021.07.027_b0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184429","article-title":"Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors","volume":"12","author":"Bretin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2021.07.027_b0530","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/FBP.0000000000000418","article-title":"New procognitive enhancers acting at the histamine H3 and AMPA receptors reverse natural forgetting in mice: comparisons with donepezil and memantine in the object recognition task","volume":"30","author":"Louis","year":"2019","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0535","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.neuropharm.2018.03.018","article-title":"The reduction in glutamate release is predictive of cognitive and emotional alterations that are corrected by the positive modulator of AMPA receptors S 47445 in perinatal stressed rats","volume":"135","author":"Morley-Fletcher","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0540","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.trci.2019.04.002","article-title":"A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms","volume":"5","author":"Bernard","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.drudis.2021.07.027_b0545","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/138945007780618517","article-title":"AMPA receptor potentiators: application for depression and Parkinson's disease","volume":"8","author":"O'Neill","year":"2007","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.drudis.2021.07.027_b0550","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0028-3908(01)00027-2","article-title":"Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro","volume":"40","author":"Miu","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0555","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1021\/jm0002836","article-title":"Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)-propanoic acid (AMPA) receptors","volume":"43","author":"Ornstein","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2021.07.027_b0560","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.106.105734","article-title":"Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of \u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors","volume":"319","author":"Ryder","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2021.07.027_b0565","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jmedchem.5b00300","article-title":"The discovery and characterization of the \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-4-(5-cyano-2-thienyl)phenoxytetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242)","volume":"58","author":"Shaffer","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2021.07.027_b0570","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1111\/j.1755-5949.2009.00088.x","article-title":"DRUG FOCUS: S 18986: a positive allosteric modulator of AMPA-type glutamate receptors pharmacological profile of a novel cognitive enhancer","volume":"16","author":"Bernard","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.drudis.2021.07.027_b0575","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00213-007-0765-4","article-title":"Improvement of episodic contextual memory by S 18986 in middle-aged mice: comparison with donepezil","volume":"193","author":"B\u00e9racoch\u00e9a","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0580","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.expneurol.2007.10.007","article-title":"Behavioral and biological effects of chronic S18986, a positive AMPA receptor modulator, during aging","volume":"210","author":"Bloss","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.drudis.2021.07.027_b0585","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neuropharm.2009.05.010","article-title":"The AMPA receptor positive allosteric modulator, S18986, is neuroprotective against neonatal excitotoxic and inflammatory brain damage through BDNF synthesis","volume":"57","author":"Destot-Wong","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0590","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00213-008-1301-x","article-title":"Effects of the AMPA receptor modulator S 18986 on measures of cognition and oxidative stress in aged rats","volume":"202","author":"Kelly","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0595","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0014-2999(00)00429-5","article-title":"Effects of S 18986\u20131, a novel cognitive enhancer, on memory performances in an object recognition task in rats","volume":"401","author":"Lebrun","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0600","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00213-011-2168-9","article-title":"S 18986 reverses spatial working memory impairments in aged mice: comparison with memantine","volume":"215","author":"Vandesquille","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.drudis.2021.07.027_b0605","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/FBP.0b013e3282feb0c1","article-title":"The AMPA modulator S 18986 improves declarative and working memory performances in aged mice","volume":"19","author":"Marighetto","year":"2008","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0610","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1472-8206.2007.00487.x","article-title":"Comparison of single vs. multiple administrations of the AMPA receptors modulator S 18986 in the object recognition task in rats","volume":"21","author":"Bertaina-Anglade","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0615","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2007.01.030","article-title":"S18986: a positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures","volume":"561","author":"Lockhart","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0620","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1017\/S1461145709991076","article-title":"Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm","volume":"13","author":"Farley","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0625","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2174\/1871527314666150429114818","article-title":"Inquiries into the biological significance of transmembrane AMPA receptor regulatory protein (TARP) \u03b3-8 through investigations of TARP \u03b3-8 null mice","volume":"14","author":"Gleason","year":"2015","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.drudis.2021.07.027_b0630","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0028-3908(00)00194-5","article-title":"Antidepressant-like actions of an AMPA receptor potentiator (LY392098)","volume":"40","author":"Li","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0635","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0028-3908(01)00006-5","article-title":"Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator","volume":"40","author":"Legutko","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0640","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0028-3908(00)00195-7","article-title":"LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons","volume":"40","author":"Baumbarger","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0645","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2003.12.023","article-title":"Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease","volume":"486","author":"O'Neill","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0650","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1527-3458.2002.tb00228.x","article-title":"LY404187: a novel positive allosteric modulator of AMPA receptors","volume":"8","author":"Quirk","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.drudis.2021.07.027_b0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(02)00066-7","article-title":"An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study","volume":"43","author":"Mackowiak","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0660","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568007043337508","article-title":"AMPA receptor potentiators for the treatment of CNS disorders","volume":"3","author":"O'Neill","year":"2004","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.drudis.2021.07.027_b0665","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.neuropharm.2006.09.001","article-title":"Molecular mechanisms of neurite growth with AMPA receptor potentiation","volume":"52","author":"Voss","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0670","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brainres.2015.01.001","article-title":"Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action","volume":"1601","author":"Andreasen","year":"2015","journal-title":"Brain Res"},{"key":"10.1016\/j.drudis.2021.07.027_b0675","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/FBP.0000000000000243","article-title":"Positive allosteric modulation of \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors differentially modulates the behavioural effects of citalopram in mouse models of antidepressant and anxiolytic action","volume":"27","author":"Fitzpatrick","year":"2016","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0680","doi-asserted-by":"crossref","unstructured":"Lindholm JS, Autio H, Vesa L, Antila H, Lindemann L, Hoener MC, et al. The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf+\/- heterozygous null mice. Neuropharmacology 2012; 62: 391\u20137.","DOI":"10.1016\/j.neuropharm.2011.08.015"},{"key":"10.1016\/j.drudis.2021.07.027_b0685","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbr.2010.03.039","article-title":"Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction","volume":"212","author":"Roberts","year":"2010","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.drudis.2021.07.027_b0690","doi-asserted-by":"crossref","first-page":"16949","DOI":"10.1523\/JNEUROSCI.4668-10.2010","article-title":"Individual stress vulnerability is predicted by short-term memory and AMPA receptor subunit ratio in the hippocampus","volume":"30","author":"Schmidt","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2021.07.027_b0695","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.npp.1301562","article-title":"AMPA receptor potentiation can prevent ethanol-induced intoxication","volume":"33","author":"Jones","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0700","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0028-3908(03)00104-7","article-title":"Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus","volume":"44","author":"Bai","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0705","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1124\/jpet.103.049445","article-title":"LY503430, a novel \u03b1-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease","volume":"306","author":"Murray","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2021.07.027_b0710","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1527-3458.2005.tb00037.x","article-title":"LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease","volume":"11","author":"O'Neill","year":"2005","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.drudis.2021.07.027_b0715","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1212\/01.wnl.0000260240.46070.7c","article-title":"AMPA potentiator treatment of cognitive deficits in Alzheimer disease","volume":"68","author":"Chappell","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2021.07.027_b0720","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1017\/S1041610212002141","article-title":"Mibampator (LY451395) randomized clinical trial for agitation\/aggression in Alzheimer's disease","volume":"25","author":"Trzepacz","year":"2013","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.drudis.2021.07.027_b0725","first-page":"CD012197","article-title":"Pharmacological interventions for apathy in Alzheimer\u2019s disease","volume":"5","author":"Ruthirakuhan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.drudis.2021.07.027_b0730","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/jamaoto.2015.0791","article-title":"The safety and efficacy of PF-04958242 in age-related sensorineural hearing loss: a randomized clinical trial","volume":"141","author":"Bednar","year":"2015","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.drudis.2021.07.027_b0735","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/mol.119.118554","article-title":"Auxiliary proteins are the predominant determinants of differential efficacy of clinical candidates acting as AMPA receptor positive allosteric modulators","volume":"97","author":"Ishii","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0740","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/mp.2017.6","article-title":"Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242","volume":"22","author":"Ranganathan","year":"2017","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.drudis.2021.07.027_b0745","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cpt.901","article-title":"Reverse and forward translational neuropharmacology in psychiatric drug discovery","volume":"103","author":"Shaffer","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2021.07.027_b0750","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pbb.2019.06.004","article-title":"TAK-137, an AMPA receptor potentiator with little agonistic effect, produces antidepressant-like effect without causing psychotomimetic effects in rats","volume":"183","author":"Suzuki","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.drudis.2021.07.027_b0755","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/bs.apha.2019.03.002","article-title":"Rapid-acting antidepressants","volume":"86","author":"Witkin","year":"2019","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0760","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.479","article-title":"Preclinical characterization of AMPA receptor potentiator TAK-137 as a therapeutic drug for schizophrenia","volume":"7","author":"Tanaka","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.drudis.2021.07.027_b0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134488","article-title":"Electrophysiological characterization of a novel AMPA receptor potentiator, TAK-137, in rat hippocampal neurons","volume":"712","author":"Suzuki","year":"2019","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.drudis.2021.07.027_b0770","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1124\/jpet.117.245050","article-title":"HBT1, a novel AMPA receptor potentiator with lower agonistic efect, avoided bell-shaped response in in vitro BDNF production","volume":"364","author":"Kunugi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2021.07.027_b0775","doi-asserted-by":"crossref","unstructured":"Chaki S, Koike H, Fukumoto K. Targeting of metabotropic glutamate receptors for the development of novel antidepressants. Chronic Stress (Thousand Oaks) 2019; 3: 2470547019837712.","DOI":"10.1177\/2470547019837712"},{"key":"10.1016\/j.drudis.2021.07.027_b0780","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17460441.2020.1822814","article-title":"Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery","volume":"16","author":"Musazzi","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.drudis.2021.07.027_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172854","article-title":"mGlu2\/3 receptor antagonism: a mechanism to induce rapid antidepressant effects without ketamine-associated side-effects","volume":"190","author":"Witkin","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.drudis.2021.07.027_b0790","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbr.2014.05.065","article-title":"Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats","volume":"271","author":"Koike","year":"2014","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.drudis.2021.07.027_b0795","first-page":"228","article-title":"Rapid and sustained antidepressant action of the mGlu2\/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine","volume":"20","author":"Dong","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_b0800","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R, 6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2021.07.027_b0805","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pbb.2013.03.017","article-title":"Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats","volume":"107","author":"Koike","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.drudis.2021.07.027_b0810","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tips.2017.03.008","article-title":"mGlu2\/3 receptor antagonists as novel antidepressants","volume":"38","author":"Chaki","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2021.07.027_b0815","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fncel.2016.00122","article-title":"New insights into reelin-mediated signaling pathways","volume":"10","author":"Lee","year":"2016","journal-title":"Front Cell Neurosci"},{"issue":"654\u201363","key":"10.1016\/j.drudis.2021.07.027_b0820","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/sj.mp.4000794","article-title":"Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression","volume":"5","author":"Fatemi","year":"2000","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.drudis.2021.07.027_b0825","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neuropharm.2013.04.012","article-title":"The progressive development of depression-like behavior in corticosterone-treated rats is paralleled by slowed granule cell maturation and decreased reelin expression in the adult dentate gyrus","volume":"71","author":"Lussier","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0830","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fncel.2016.00048","article-title":"Reelin-related disturbances in depression: implications for translational studies","volume":"10","author":"Caruncho","year":"2016","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.drudis.2021.07.027_b0835","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41386-020-0609-z","article-title":"Fast-acting antidepressant-like effects of Reelin evaluated in the repeated-corticosterone chronic stress paradigm","volume":"45","author":"Brymer","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2021.07.027_b0840","doi-asserted-by":"crossref","first-page":"12943","DOI":"10.1523\/JNEUROSCI.2561-06.2006","article-title":"Differential reelin-induced enhancement of NMDA and AMPA receptor activity in the adult hippocampus","volume":"26","author":"Qiu","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2021.07.027_b0845","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.559627","article-title":"Ketamine rescues hippocampal reelin expression and synaptic markers in the repeated-corticosterone chronic stress paradigm","volume":"11","author":"Johnston","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2021.07.027_bib871","article-title":"A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action","volume":"118","author":"Kim","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2021.07.027_b0850","doi-asserted-by":"crossref","first-page":"6503162","DOI":"10.1155\/2016\/6503162","article-title":"Coping with the forced swim stressor: towards understanding an adaptive mechanism","volume":"2016","author":"de Kloet","year":"2016","journal-title":"Neural Plast"},{"key":"10.1016\/j.drudis.2021.07.027_b0855","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3357\/ASEM.2055.2007","article-title":"Ampakine (CX717) effects on performance and alertness during simulated night shift work","volume":"78","author":"Wesensten","year":"2007","journal-title":"Aviat Space Environ Med"},{"key":"10.1016\/j.drudis.2021.07.027_b0860","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.bmcl.2010.07.138","article-title":"A novel series of positive modulators of the AMPA receptor: discovery and structure based hit-to-lead studies","volume":"20","author":"Jamieson","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2021.07.027_b0865","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/jpet.104.078196","article-title":"Positive \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators have different impact on synaptic transmission in the thalamus and hippocampus","volume":"313","author":"Xia","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2021.07.027_b0870","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2010.08.004","article-title":"Lessons from more than 80 structures of the GluA2 ligand-binding domain in complex with agonists, antagonists and allosteric modulators","volume":"60","author":"P\u00f8hlsgaard","year":"2011","journal-title":"Neuropharmacology"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621003536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:53:23Z","timestamp":1761224003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621003536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":175,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1359644621003536"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.07.027","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}